Apilimod
Alternative Names: Apilimod mesylate; STA-5326; STA-5326 mesylateLatest Information Update: 04 Nov 2017
At a glance
- Originator Synta Pharmaceuticals
- Developer Madrigal Pharmaceuticals; Synta Pharmaceuticals
- Class Antidementias; Antineoplastics; Antivirals; Hydrazines; Morpholines; Pyrimidines; Small molecules
- Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
- Discontinued Common variable immunodeficiency; Crohn's disease; Psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
- 22 Jul 2016 Madrigal Pharmaceuticals merged with Synta Pharmaceuticals and the combined company is now called as Madrigal Pharmaceuticals
- 09 Oct 2008 Apilimod is still in phase II trials for Crohn's disease in USA and rheumatoid arthritis in Netherlands